CompoAtlas

WOMEN'S 50+ MULTIVITAMINS & MINERALS

Food supplement declared in France, declaration No 2023-9-386, decision dated 7 September 2023

WOMEN'S 50+ MULTIVITAMINS & MINERALS (HORBÄACH) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Vaccinium macrocarpon 2 mg per day, Pantothenic acid (vitamin B5), Biotin (vitamin B8), Calcium, Chromium. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
HORBÄACH
Food business operator placing the product on the market
PIPING ROCK UK LIMITED
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Tablet
Daily dose
2 comprimés par jour
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), History of breast cancer, Pregnant women, Taking anticoagulants, Taking thyroid medication, Prolonged use

Declaration 244353, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Vaccinium macrocarpon AitonFruitExtrait sec hydroalcoolique2 mg

Other active ingredients

NamePer day
Citroflavonoïdesnot declared
Lutéinenot declared
Ubiquinonenot declared
isoflavones issues de Glycine max. (L.) Merr.not declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-pantothenate, calciumPantothenic acid (vitamin B5)no limit (insufficient data)dose annulled by the French Council of State in 2011
D-biotinBiotin (vitamin B8)no limit (insufficient data)dose annulled by the French Council of State in 2011
calcium salts of orthophosphoric acidCalcium2,500 mg800 mg
chromium picolinateChromiumno limit (insufficient data)25 µg
cupric gluconateCopper5,000 µg2,000 µg
ferrous bisglycinateIron40 mg (safe level)14 mg
pteroylmonoglutamic acidFolate (vitamin B9)1,000 µg200 µg
potassium iodideIodine600 µg150 µg
magnesium oxideMagnesium250 mg300 mg
manganese sulphateManganese8 mg (safe level)3.5 mg
nicotinamideNicotinamide (vitamin B3)900 mg54 mg
sodium seleniteSelenium255 µg50 µg
retinyl acetateVitamin A3,000 µg d'équivalent rétinol800 µg
thiamin hydrochlorideVitamin B1 (thiamine)no limit (insufficient data)dose annulled by the French Council of State in 2011
cyanocobalaminVitamin B12no adverse effect defineddose annulled by the French Council of State in 2011
riboflavinVitamin B2 (riboflavin)no limit (insufficient data)dose annulled by the French Council of State in 2011
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
D-alpha-tocopheryl acid succinateVitamin E300 mg30 mg
menaquinoneVitamin Kno limit (insufficient data)dose annulled by the French Council of State in 2011
zinc oxideZinc25 mg15 mg

Additives

E460, E470b, E551, E464, E422, E903

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ne pas dépasser la dose journalière recommandée. Tenir hors de la portée des jeunes enfants. Si vous allaitez, si vous prenez des médicaments ou si vous avez des réactions inattendues, consultez votre médecin. Déconseillé aux personnes souffrant de maladies ayant pour conséquence une accumulation anormale de fer, aux femmes enceintes ou désireuses de l’être, ainsi qu’aux femmes ménopausées. Déconseillé aux personnes souffrant de troubles de la thyroïde et aux personnes sous traitement anticoagulant. Usage prolongé déconseillé. Déconseille aux femmes ayants des antécédents personnels ou familiaux de cancer du sein. Ne convient pas aux personnes de moins de 18 ans. Ne pas utiliser si le sceau sous le bouchon est cassé. Les compléments alimentaires ne doivent pas être utilisés comme substituts d'un régime alimentaire varié et équilibré et d'un mode de vie sain.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium macrocarpon Aiton
    Read the warning, when it applies and the studies cited

    CRANBERRY - VACCINIUM MACROCARPON

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    DRIED CRANBERRY JUICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : HORBÄACH

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “WOMEN'S 50+ MULTIVITAMINS & MINERALS (HORBÄACH): composition and regulation”, https://compoatlas.com/en/supplements/products/244353-women-s-50-multivitamins-minerals, updated 15 November 2026.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line